PHARMACOECONOMIC ANALYSIS OF STATIN TABLETS - IN VITRO PERFORMANCE PERSPECTIVE

Vidyavathi M; Koteswaramma L; Krishnaveni A; Madhuri T; Sarada B

doi:10.22159/ajpcr.2018.v11i7.23670

Authors

Vidyavathi M Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati â€“ 517 502, Andhra Pradesh, India.
Koteswaramma L Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati â€“ 517 502, Andhra Pradesh, India.
Krishnaveni A Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati â€“ 517 502, Andhra Pradesh, India.
Madhuri T Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati â€“ 517 502, Andhra Pradesh, India.
Sarada B Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati â€“ 517 502, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i7.23670

Keywords:

Pharmacoeconomic analysis, Statin tablets, Simvastatin, Atorvastatin, Rosuvastatin, Cost-effectiveness, Cost minimization

Abstract

Objective: Pharmacoeconomics refers to the scientific discipline that compares the value of pharmaceutical drugs or drug therapies. The pharmacoeconomic analysis includes the research methods related to cost minimization, cost-effectiveness, and cost-benefit analysis. The present study concerned with the pharmacoeconomic analysis of statin tablets (simvastatin [S1-S5], atorvastatin [A1-A5], and rosuvastatin [R1-R5]) of different brands which are varying in their prices using in vitro evaluation methods of tablets.

Methods: Weight variation, friability, hardness, disintegration, and dissolution tests of all selected statin tablets were performed as per official procedure for the pharmacoeconomic comparative analysis.

Results: It was found the least T90% with S5 and high T90% with S1 tablets among simvastatin tablets, the least T90% was observed with A1 and A5 and high T90% with A2 tablets among atorvastatin tablets, and least T 90% was observed with R5 and high T90% with R2 was found among rosuvastatin tablets without any relation with their order of prices. Hence, the study concluded that there is no significant correlation between cost and in vitro performance as there is no excellent in vitro performance found from the costliest tablets and vice versa.

Conclusion: The range of the cost of different marketed statin tablets is from Rs.17.5 to Rs.127.0 per a strip of 10 tablets. All brands of three drugs have equal strength which are assumed to produce the same outcomes. As there is no significant correlation between cost and results of some of in vitro parameters of the tablets, the cost minimization analysis can be ruled out for these brands of S1 to

Downloads

Download data is not yet available.

References

McGhan WF. International society for pharmacoeconomics and outcomes research: Visions for the 21st Century. Clin Ther 1996;18:1-4.

McGhan WF, Smith MD. Economic analysis of pharmacists counseling on patient smoking cessation outcomes: A national study. Am J Health Syst Pharm 1996;53:45-52.

Rascat KL. Essentials of pharmacoeconomics. Am J Pharm Educ 2009;73:94.

McGhan WF, Rowland CR, Boot Man JL. Cost-benefit and cost-effectiveness methodologies applied to innovative pharmaceutical services. Am J Hosp Pharm 1978;35:133-40.

Sulmasy DP, Physicians. Cost control and ethics. Ann Intern Med 1992;116:920-6.

Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol 2007;25:180-6.

Rao KS, Nundy M, Dua AS. National Commission on Macroeconomics and Health. Financing and Delivery of Health Care Services in India. New Delhi: Ministry of Health Care Services in India: Delivery of Health Services in the Private Sector; 2005. p. 89-104.

Bhanuprakash K, Divyashanthi CM. Pharmacoeconomic analysis of drugs used for peptic ulcer in Indi. Int J Basic Clin Pharmacol 2016;5:1672-7.

Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral anti diabetic drug avilable in india market. Int J Med Res Health Sci. 2013;2:63-9.

Adam T, Evans DB, Murray CJ. Econometric Estimation of Country- Specific Hospital Costs, Cost Effectiveness and Resource Allocation; 2009. Available from: http://www.resource allocation.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Ind J Pharm Sci 2007;69:160-3.

Laxminarayana K, Satish GR. Cost variation analysis of antihypertensive drugs available in indian market: An economic perspective: Int J Pharm Sci Res 2016;7:2050-6.

Sangram V, Rakshith V, Murari CH, Venkateshwarlu K. A study on symptoms, risk factors and prescribing pattern of drugs used in stroke patients. Int J Pharm Pharmsci 2015;7:421-6.

Affandi MM, Minaketantripathya B, Majeed AB. The prospect, promises and hindrances of statin base molecules: Look back to look forward. Int J Pharm Pharmsci 2016;8:22-33.

Mohammad AK, Murti K, Vaibhav G, Lal K, Singh D, Das P, et al. Aatorvastatinvsrosuvastatin; fenofibrate as an add on: An exploratory study. Int J Pharm Pharmsci 2014;6:493-8.

Jainam VS, Kalyani NP, Deshpandeshrikalp S. Pharmacoeconomics evaluation, cost minimization analysis of Anti-diabetic therapy in Gujarat. Int J Med Res Health Sci 2006;5:34-43.

Abhishek MP, Jitendra HH, Kiran RD, Sagar SP, Madhura N. Cost analysis of long established and newer oral antiepileptic drugs available in the Indian market. Int J Med Res Health Sci 2015;4:744-8.

Lalan HN, Borde MK, Ray IM, Deshmukh YA. Cost variation study of antidiabetics: Indian scenario. Indian J Appl Res 2014;4:420-1.

Fonner DA, Anderson NR, Banker GS. Granulation and tablet characteristics. In: Libermann H, Lachmann L, editor. Pharmaceutical Dosage Forms: Tablets. Vol 2. New York: Dekker; 1982. p. 202.

Indian Pharmacopoeia. Govt.of India, Ministry of health and Family welfare, The Indian pharmacopoeia Commission, Ghaziabad, India. Indian Pharmacopoeia. Vol. 2, Appendix 7, A-80 for Disintegration, A-82 for Dissolution Procedures, Edition. Ghaziabad, India: Govt.of India, Ministry of health and Family Welfare; 1996.

Paunikar AP, Bhave KA. Cost analysis of oral antidepressant drugs available in India. Natl J Physiol Pharm Pharmacol 2015;5:367-71.